Latest Mental Health News

Qoria Limited reported a robust FY2025 with 25% growth in annual recurring revenue and a 684% jump in EBITDA, underscoring its expanding leadership in global K12 safety and wellbeing platforms.

RAM Essential Services Property Fund reported solid FY25 results, highlighting portfolio growth, strategic capital recycling, and a clear transition towards a pure healthcare real estate focus.

Emyria has begun treating the first Medibank-funded PTSD patients at its Perth clinic, marking a pioneering step in private insurance coverage for psychedelic-assisted therapy in Australia. This milestone fuels rapid clinic expansion and supports the company’s national rollout strategy.

Peet Limited delivered a robust FY25 performance with a 60% jump in net operating profit and a strong sales pipeline, while initiating a strategic review to capitalize on favorable market conditions.

Tryptamine Therapeutics has secured an exclusive agreement with leading neuroscientists to develop a novel EEG-based brain entropy biomarker aimed at enhancing precision psychiatry for its psychedelic drug TRP-8803.

IPH Limited reported a solid 16.5% revenue increase to $710.3 million for FY25, driven by strategic acquisitions in Canada and strong organic growth in Asia and ANZ. Despite ongoing delays at the Canadian Intellectual Property Office, the company achieved higher earnings and dividends, setting the stage for further operational efficiencies and technology investments.

Dexus’s 2025 annual results reveal stable cash flows, robust occupancy rates, and a positive shift in property valuations, underscoring its resilience amid evolving market conditions. The company’s sustainability leadership and strategic divestments position it well for the next growth phase.

Dexus has reported FY25 results that meet guidance, showcasing resilience in its office and industrial portfolios alongside strong funds management performance. The company signals optimism for the next phase of the real estate cycle despite ongoing market uncertainties.

Doctor Care Anywhere has reported a landmark positive operating and investing cash inflow in Q2 2025, alongside modest consultation growth and strategic service expansion. The company reiterates its ambitious revenue and profitability targets amid ongoing cost transformation.

TrivarX has secured key approvals and begun recruiting for its innovative mental health screening trial in US veterans, while also launching a wearable tech pilot with a Major League Baseball academy in the Dominican Republic.

Emyria has inked a pivotal agreement with Avive Health to launch its first Empax clinic in Queensland, expanding its innovative mental health treatment network. This move builds on its recent Medibank partnership, advancing accessible, reimbursed care for treatment-resistant conditions.

Emyria has secured a landmark multi-year funding agreement with Medibank to reimburse PTSD patients under its Empax program, alongside opening a second clinic and reporting durable clinical improvements in treatment-resistant PTSD cases.